Equal Weekly Volume Leaves Resistance Training Frequency Without a Clear Hypertrophy Edge
A new systematic review and meta-analysis brings one of strength training’s recurring debates back into focus: when weekly work is held constant, does training a muscle once, twice, or three times per week change the size of the hypertrophy response? Across 16 trials and 380 participants, the answer was essentially no. The pooled estimate for training frequency was trivial and non-significant, with a Hedges g of –0.06 and a 95% confidence interval from –0.24 to 0.13.
The practical implication is straightforward. If total weekly volume is already matched, frequency alone did not separate the muscle-growth signal across the range tested in these trials.
That result fits a basic physiological premise. Muscle protein synthesis, remodeling, and recovery appear to respond most strongly to the accumulated weekly stimulus, while session spacing may matter less once the same workload is delivered over the week. In other words, the muscle seems to care more about how much high-quality work it receives than how that work is partitioned across one, two, or three sessions, at least within the narrow experimental range studied here.
What the Trial Pool Actually Measured
The review followed PRISMA 2020 methods and searched five databases through October 2026 for trials lasting at least six weeks. Only studies that equated weekly volume between different per-muscle training frequencies and measured muscle size were eligible. The authors then pooled one change-score standardized mean difference per trial using a random-effects model and rated certainty with GRADE.
Sixteen trials formed the analytic base. The abstract does not list the full demographic breakdown, and no additional participant characteristics should be inferred beyond the total sample size of 380. What does stand out is the consistency of the finding: heterogeneity was absent, with I² at 0%, and the prediction interval ranged from –0.26 to 0.14. Even that interval leaves room only for a small possible benefit for higher frequency, not a clinically meaningful separation.
The contrast-specific analyses tell a similar story. One versus two sessions and two versus three sessions were both trivial and non-significant. The one-versus-three comparison leaned slightly toward higher frequency, with a small effect estimate of g = –0.23, but the confidence interval remained wide and crossed no-effect. The data do not justify turning that estimate into a rule for programming.
Why Muscle Thickness Is a Blunt Endpoint
One of the most important cautions in the paper concerns the outcome measure itself. Most trials used muscle thickness, a convenient and widely available proxy, but one that does not map reliably onto whole-muscle growth. Ultrasound thickness can miss regional hypertrophy, architecture changes, and shifts in pennation angle that alter the relationship between measured thickness and true muscle enlargement.
This matters because a frequency effect could be obscured if the endpoint is insensitive to where growth is occurring in the muscle. If one session distribution changes intramuscular remodeling patterns rather than total volume, thickness alone may not capture the difference. The absence of a detectable signal in these studies therefore reflects both biology and measurement limits.
Still, the most defensible reading of the pooled evidence is that the weekly dose is doing the heavy lifting. Once that dose is equalized, splitting it into fewer or more sessions does not appear to produce a consistent hypertrophy advantage in the available trials.
Low Certainty, Small Signals, and Narrow Detection Power
GRADE certainty was low to very low, which tempers the strength of any recommendation. The moderator analyses also failed to show any significant effect, but the investigators note an important limitation: those analyses were powered to detect only large effects. Smaller but potentially relevant differences could have escaped detection.
The evidence base is therefore not strong enough to rule out every possible frequency-related nuance. It does, however, argue against the common assumption that more frequent training automatically means more growth when volume is matched. For athletes and recreational lifters alike, that distinction can influence planning, recovery, and adherence. Some people may prefer three shorter sessions because they fit better into a week; others may recover better with fewer, denser sessions. The pooled data do not identify hypertrophy as the deciding factor.
A quiet but important feature of the findings is their stability. The pooled estimate shifted only modestly in the revised version after the Neves et al. (2022) input was changed from the volume-load-equated condition to the sets-equated condition to align with the rest of the analysis. The updated pooled result moved from g = –0.02 to g = –0.06, while the one-versus-three comparison shifted from –0.12 to –0.23. The conclusions did not change.
What This Means for Programming at the Gym Floor
For resistance-trained people trying to build muscle, the most defensible priority remains total weekly volume, followed by exercise selection, effort, recovery, and long-term progression. Frequency can still be used as an organizational tool, but this analysis offers no basis for choosing one, two, or three sessions per muscle per week on hypertrophy grounds alone when volume is matched.
That is a useful correction to a common habit of over-weighting schedule frequency and under-weighting workload. A lifter who can better sustain quality sets with two sessions may gain no less than one who spreads the same work across three. A lifter who needs more frequent, shorter sessions to maintain technique or manage fatigue may do just as well. The muscle-growth outcome appears remarkably similar across those choices in the current trial set.
What remains unresolved is whether longer studies, more sensitive imaging methods, or larger samples would reveal small but real frequency differences. The current evidence does not show them. It also does not support treating higher frequency as inherently superior for hypertrophy at a fixed weekly dose.